AMLX Amylyx Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1658551 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.3%
TTM net income YoY42.5%
TTM EPS YoY53.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin100.0%
Operating margin23,660.3%
Net margin22,448.4%
FCF margin23,236.1%
EBITDA margin23,573.5%
Returns
ROE-56.5%
ROA-48.7%
ROIC (approx.)-107.5%
Asset turnover-0.00x
Leverage & solvency
Liabilities / assets8.5%
Debt / equity0.00x
Current ratio13.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.7%
Payout ratio—
Capex / revenue-10.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $87.37M |
| Cost of revenue | $0 | $5.95M |
| Gross profit | $0 | $81.42M |
| R&D expense | $90.40M | $104.08M |
| SG&A expense | $62.89M | $114.33M |
| Operating income | -$153.29M | -$314.73M |
| Pretax income | -$144.69M | -$302.14M |
| Income tax | $46,000 | -$393,000 |
| Net income | -$144.74M | -$301.74M |
| EBITDA | -$152.77M | -$313.83M |
| EPS (basic) | -1.53 | -4.43 |
| EPS (diluted) | -1.53 | -4.43 |
| Weighted avg. shares (diluted) | 94.57M | 68.14M |
| Balance sheet | ||
| Cash & equivalents | $226.65M | $77.39M |
| Short-term investments | $90.33M | $99.11M |
| Receivables | $88,000 | $447,000 |
| Current assets | $323.67M | $189.43M |
| PP&E, net | $310,000 | $961,000 |
| Total assets | $332.64M | $193.63M |
| Current liabilities | $22.69M | $28.41M |
| Total liabilities | $27.39M | $28.87M |
| Shareholders' equity | $305.26M | $164.76M |
| Shares outstanding | 109.88M | 68.63M |
| Cash flow statement | ||
| Operating cash flow | -$123.34M | -$167.65M |
| Capital expenditure | $138,000 | $157,000 |
| Free cash flow | -$123.48M | -$167.80M |
| Investing cash flow | $14.04M | $75.65M |
| Financing cash flow | $257.03M | $348,000 |
| Depreciation & amortization | $525,000 | $904,000 |
| Stock-based compensation | $27.64M | $33.04M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.